NCT03654911 · COMPLETED
Sustainable Method for Alzheimer's Prediction
This observational study is testing whether a combination of brainwave recordings (EEG), neuropsychological testing, and APOE genotyping can reliably predict which people with mild memory problems will go on to develop Alzheimer's. No phase is listed because no drug or treatment is being given — researchers are watching and measuring, not intervening. The goal is to find a simpler, lower-cost early screening approach.
Eligibility criteria
Exclusion criteria for AD will be: * frontotemporal dementia; * behavioural variant of frontotemporal dementia; * vascular dementia; * extra-pyramidal syndromes; * reversible dementias (including pseudodementia of depression); * Lewy body dementia. The exclusion criteria for aMCI will be: * mild AD, as diagnosed by standard protocols including National Institute on Aging-Alzheimer's Association workgroups (McKhann et al. 2011); * evidence (including magnetic resonance imaging -MRI procedures) of concomitant dementia such as frontotemporal, vascular and reversible dementias (including pseudo-depressive dementia), marked fluctuations in cognitive performance compatible with Lewy body dementia and/or features of mixed dementias; * evidence of concomitant extrapyramidal symptoms; * clinical and indirect evidence of depression as revealed by the Geriatric Depression Scale GDS (Yesavage et al. 1982); scores lower than 14 (no depression); * other psychiatric diseases, epilepsy, drug addiction, alcohol dependence, use of neuro/psychoactive drugs including acetylcholinesterase inhibitors; * current or previous uncontrolled or complicated systemic diseases (including diabetes mellitus) or traumatic brain injuries.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2020-07-22